IJSTR

International Journal of Scientific & Technology Research

Home About Us Scope Editorial Board Blog/Latest News Contact Us
0.2
2019CiteScore
 
10th percentile
Powered by  Scopus
Scopus coverage:
Nov 2018 to May 2020

CALL FOR PAPERS
AUTHORS
DOWNLOADS
CONTACT

IJSTR >> Volume 9 - Issue 5, May 2020 Edition



International Journal of Scientific & Technology Research  
International Journal of Scientific & Technology Research

Website: http://www.ijstr.org

ISSN 2277-8616



A Review On Neurodegenerative Diseases: Types, Pathology & Recent Advancement In Neurodegenerative Treatment

[Full Text]

 

AUTHOR(S)

Gomathi Kannayiram, Dhivya V, Raghavi Suresh, Prathiksha Prabhakar, Pooja Pushkarni P, Sandhya A

 

KEYWORDS

Alzheimer’s disease, β amyloid plaques, Dopaminergic neurons, Familial Alzheimer’s disease (FAD), Induced pleuripotent stem cells (iPSCs), Neurofibrillary tangles (NFT), Substantia nigra.

 

ABSTRACT

Neurodegenerative diseases are characterised by the progressive loss of selective population of neurons thereby breaking the synaptic circuit and these diseases are rapidly increasing in prevalence. The most common neurodegenerative diseases are Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis. Often these diseases result in loss of memory, uncontrolled movements, lack of coordination, slurred speech and other body impairments. The brain is a complex organ made up of billions of cells on which we depend for proper functioning. Some of the most essential cells in the brain are called “Neurons” .These neurons communicate with each other to perform every function of the brain. .These neurons are interconnected and any miscommunication in one area can affect other activities of the brain leading to neural disordersThe death of the neurons in Alzheimer’s disease is caused by the accumulation of β amyloid plaques and tau protein extracellularly. In case of Huntington’s disease the expansion of CAG tri-nucleotide repeat in the huntingtin gene is the cause. This review offers a brief introduction to neurodegenerative diseases and provides an overview of its types and pathology. It also touches upon the recent advancement in the treatment of neurodegenerative diseases. In this review we have attempted to summarize the symptoms, pathology and treatment of three main neurodegenerative diseases namely; Alzheimer’s disease, Parkinson’s disease , Huntington’s disease.

 

REFERENCES

[1]. Current Concepts of Neurodegenerative Mechanisms in Alzheimer’s Disease Kasthuri Bai Magalingam,1,2 Ammu Radhakrishnan,1 Ng Shee Ping,2 and Nagaraja Haleagrahara3 Volume 2018 |Article ID 3740461 | 12 pages | https://doi.org/10.1155/2018/3740461
[2]. Neurodegenerative disease: models, mechanisms, and a new hope Aaron D. Gitler,1,* Paraminder Dhillon,2 and James Shorter3,* Dis Model Mech. 2017 May 1; 10(5): 499–502.doi: 10.1242/dmm.030205
[3]. What are Neurodegenerative Diseases and How Do They Affect the Brain? Berman T and Bayati A (2018). Front. Young Minds. 6:70. doi: 10.3389/frym.2018.00070
[4]. Neurodegenerative diseases : Heemels, M. Neurodegenerative diseases. Nature 539, 179 (2016). https://doi.org/10.1038/539179a
[5]. Alzhiemer’s Disease:Past, Present and future.2018 Mark W.Bondi, Emily C. Edmonds and David P. Salmon
[6]. A Critical overview of therapeutic strategy and advancement for Alzheimer’s Disease treatment.2017 Yung-Chin Kuo, rajendiran Rajesh
[7]. update on Alzheimer’s disease: Recent findings and treatment.2000 Ruth O’Hara, Martin Smumenthaler and Jerome A yesavage.
[8]. Ibanez C , Simo C , Martin-Alvarez PJ , Kivipelto M , Winblad B , Ceda- zo-Mínguez A , et al. Toward a predictive model of Alzheimer’s disease pro- gression using capillary electrophoresis-mass spectrometry metabolomics. Anal Chem 2012;84:8532–40 .
[9]. Korolev IO . Alzheimer’s disease: a clinical and basic science review. Med Stu- dent Res J 2014;4:24–33 .
[10]. Kumar A , Singh A , Ekavali . A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 2015;67:195–203 .
[11]. Genetic of Alzheimer’s disease: A narrative review article. 2015 Mohammad Khanahmadi, Darish D. Farhud and Maryam Malmir
[12]. Nutrition and it’s effect on Alzheimer’s Disease Nutrition and Health. 2014 Khanahamdi M,Malmir M and Farhud D
[13]. Genetic risk factors for dementia edited by WK, editors. Blackwel publishing Hollingworth P, Williams J. 2011
[14]. Alzheimer’s Association Alzheimer’s disease facts and figures. Alzheimers De- mentia 2015;11:332–84 .
[15]. Ridha BH , Barnes J , Bartlett JW , Godbolt A , Pepple T , Rossor MN , et al. Track- ing atrophy progression in familial Alzheimer’s disease: a serial MRI study. Lancet Neurol 2006;5:828–34 .
[16]. Suram A , Hedge ML , Rao KSJ . A new evidence for DNA nicking property of amyloid β-peptide (1–42): relevance to Alzheimer’s disease. Arch Biochem Biophys 2007;463:245–52 .
[17]. Findies MA . The role of amyloid βpeptide 42 in Alzheimer’s disease. Phar- macol Ther 2007;116:266–86 .
[18]. Hu X , Crick SL , Buc G , Frieden CL , Pappu RV , Lee JM . Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci USA 2009;106:20324–9 .
[19]. SavelieffMG , Lee S , Liu Y , Lim MH . Untangling amyloid- β, tau, and metals in Alzheimer’s disease. ACS Chem Biol 2013;8:856–65 .
[20]. Tamagnoa E , Bardini P , Guglielmotto M , Danni O , Tabaton M . The various aggregation states of β-amyloid 1–42 mediate different effects on oxida- tive stress, neurodegeneration, and BACE-1 expression. Free Radical Biol Med 2006;41:202–12 .
[21]. Benilova I , Karran E , Strooper BD . The toxic A βoligomer and Alzheimer’s dis- ease: an emperor in need of clothes. Nat Neurosci 2012;15:349–57 .
[22]. Lee J , Culyba EK , Powers ET , Kelly JW . Amyloid-beta forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol 2011;7:602–9 .
[23]. Turner PR , O’Connor K , Tate WP , Abraham WC . Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 2003;70:1–32 .
[24]. Hansson O , Zetterberg H , Vanmechelen E , Vanderstichele H , Andreasson U , Londos E , et al. Evaluation of plasma A â40 and A â42 as predictors of con- version to Alzheimers disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31:357–67 .
[25]. Hardy J , Selkoe DJ . The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002;297:353–6
[26]. Walsh DM , Klyubin I , Fadeeva JV , Cullen WK , Anwyl R , Wolfe MS , et al. Nat- urally secreted oligomers of amyloid bold beta protein potently inhibit hip- pocampal long-term potentiation in vivo . Nature 2002;416:535–9 .
[27]. Wilson DM , Binder LI . Free fatty acids stimulate the polymerization of tau and amyloid βpeptides. In Vitro Evidence for a common effector of patho- genesis in Alzheimer’s disease. Am J Pathol 1997;150:2181–95 .
[28]. Rissman RA , Poon WW , Blurton-Jones M , Oddo S , Torp R , Vitek MP , et al. Cas- pase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 2004;114:121–30 .
[29]. LaFerla FM , Oddo S . Alzheimer’s disease: A β, tau and synaptic dysfunction. Trends Mol Med 2005;4:170–6 .
[30]. Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer’s disease. Neurochemistry International. 2011; 58(4): 458 -471.
[31]. Soto C. Alzheimer’s and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches. Journal of Molecular Medicine. 1999;77(5):412–418. [PubMed] [Google Scholar]
[32]. Sergeant N, Delacourte A, Buée L. Tau protein as a differential biomarker of tauopathies. Biochimica et Biophysica Acta. 2005;1739(2):179–197. [PubMed] [Google Scholar]
[33]. Iqbal K, Liu F, Gong CX, del Alonso AC, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathologica. 2009;118(1):53–69. [PMC free article] [PubMed] [Google Scholar]
[34]. Khatoon S, Grundke-Iqbal I, Iqbal K. Levels of normal and abnormally phosphorylated tan in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Letters. 1994;351(1):80–84. [PubMed] [Google Scholar]
[35]. Alonso ADC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(12):5562–5566. [PMC free article] [PubMed] [Google Scholar]
[36]. Li B, Chohan MO, Grundke-Iqbal I, Iqbal K. Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. Acta Neuropathologica. 2007;113(5):501–511. [PMC free article] [PubMed] [Google Scholar]
[37]. Wang JZ, Gong CX, Zaidi T, Grundke-Iqbal I, Iqbal K. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. The Journal of Biological Chemistry. 1995;270(9):4854–4860. [PubMed] [Google Scholar]
[38]. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: a report of the NINCDS-ADRDA work-group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944. [PubMed] [Google Scholar]
[39]. Mayeaux R. Predicting who will develop Alzheimer's disease. In: Mayeaux R, Christen Y, eds. Epidemiology of Alzheimer's disease: from gene to prevention. New York: Springer-Verlag, 1999:19-31.
[40]. Peterson RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308. [PubMed] [Google Scholar]
[41]. Small GW. Treatment of Alzheimer's disease: current approaches and promising developments. Am J Med 1998;104(suppl):32-38S. [PubMed] [Google Scholar]
[42]. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging. Neurology 1997;48:1517-1521. [PubMed] [Google Scholar]
[43]. Henderson VW. The epidemiology of Alzheimer's disease: the role of estrogen in reducing risk. In: Mayeaux R, Christen Y, eds. Epidemiology of Alzheimer's disease: from gene to prevention. New York: Springer-Verlag; 1999:49-63.
[44]. Honjo H, Ogino Y, Tanaka K, et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: a placebo-controlled, double-blind study. J Jpn Menopause Soc 1993;1:167-171. [Google Scholar]
[45]. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind pilot study. Psychoneuroendocrinology 1999;24:657-677. [PubMed] [Google Scholar]
[46]. Behl C, Skutella T, Lezoualch F, et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997;51:535-541. [PubMed] [Google Scholar]
[47]. Nathan L, Chaubhuri G. Antioxidant and prooxidant actions of estrogens: potential physiological and clinical implications. Semin Reprod Endocrinol 1998;16:309-314. [PubMed] [Google Scholar]
[48]. Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688-695. [PubMed] [Google Scholar]
[49]. Consensus on diagnosis and treatment of dementia: summary of recommendations. American Geriatric Society Symposia May 1998:13-14.
[50]. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384–6. [PubMed] [Google Scholar]
[51]. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62:10–5. [PMC free article] [PubMed] [Google Scholar]
[52]. Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat. Disord. 2016;22(Suppl. 1):S41–S46. [PubMed] [Google Scholar]
[53]. An update on the diagnosis and treatment of Parkinson disease. Philippe Rizek, MD, Niraj Kumar, MD DM, and Mandar S. Jog, MD
[54]. Scope (prevalence and incidence) of neurological conditions. In: Mapping connections: an understanding of neurological conditions in Canada. Ottawa: Public Health Agency of Canada; 2014. Available: www.phac-aspc.gc.ca/publicat/cd-mc/mc-ec/section-3-eng.php (accessed 2015 Aug. 30). [Google Scholar]
[55]. Krack P, Martinez-Fernandez R, del Alamo M, Obeso JA. Current applications and limitations of surgical treatments for movement disorders. Mov Disord. 2017; 32(1):36–52. [PubMed: 28124435]
[56]. Parent M, Parent A. Substantia nigra and Parkinson’s disease: a brief history of their long and intimate relationship. Can J Neurol Sci. 2010; 37(03):313–319. [PubMed: 20481265]
[57]. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24:197–211. [PubMed] [Google Scholar]
[58]. Jankovic J. Progression of Parkinson disease: Are we making progress in charting the course? Arch Neurol 2005;62:351–2. [PubMed] [Google Scholar]
[59]. Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord. 2014; 30(1):4–18. [PubMed: 25491387]
[60]. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol. 2009; 8(12):1150–1157. [PubMed: 19909913]
[61]. Michel PP, Hirsch EC, Hunot S. Understanding dopaminergic cell death pathways in Parkinson disease. Neuron. 2016; 90(4):675–691. [PubMed: 27196972]
[62]. Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JPA. Environmental risk factors and Parkinson’s disease: an umbrella review of meta-analyses. Parkinsonism Relat Disord. 2016; 23:1– 9. [PubMed: 26739246]
[63]. Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:968–75. [PubMed] [Google Scholar]
[64]. Marttila RJ, Rinne UK: Progression and survival in Parkinson's disease. Acta Neurol Scand Suppl 1991; 136:24-2
[65]. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368–76.
[66]. Baumann CR. Epidemiology, diagnosis and differential diagnosis in Parkinson’s disease tremor. Parkinsonism Relat Disord 2012;18:S90–2.
[67]. LeWitt PA, Fahn S. Levodopa therapy for Parkinson disease: a look backward and forward. Neurology. 2016; 86(14 suppl 1):S3–S12. [PubMed: 27044648
[68]. Physiotherapy should address fixed motor features like falls, freezing and deconditioning. For patients with early disease, it is reasonable to endorse exercise (e.g., gym settings, regular walks or even dance therapy)
[69]. Volpe D, Signorini M, Marchetto A, et al. A comparison of Irish set dancing and exercises for people with Parkinson’s disease: a phase II feasibility study. BMC Geriatr 2013;13:54. [PMC free article] [PubMed] [Google Scholar]
[70]. Genetics of Huntington Disease S.Mahalingam and L.M. Levy American Journal of Neuroradiology June 2014, 35 (6) 1070- 1072; DOI: https://doi.org/10.3174/ajnr.A3772
[71]. Huntington's disease: a clinical review Raymund AC Roos 1 Orphanet J Rare Dis. 2010; 5: 40.Published online 2010 Dec 20. doi: 10.1186/1750-1172-5-40PMCID: PMC3022767 PMID: 21171977
[72]. Huntington disease: a single gene degenerative disorder of the striatum Nopoulos PC. Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin Neurosci. 2016;18(1):91–98.
[73]. Pathophysiology of Huntington’s Disease: Time-Dependent Alterations in Synaptic and Receptor Function: Lynn A. Raymond,1 Véronique M. André,2 Carlos Cepeda,2 Clare M. Gladding,1 Austen J. Milnerwood,1 and Michael S. Levine2 Neuroscience. 2011 Dec 15; 198: 252–273. PMCID: PMC3221774 NIHMSID: NIHMS321948 PMID: 21907762
[74]. GENETICS AND NEUROPATHOLOGY OF HUNTINGTON’S DISEASE :Anton Reiner,1 Ioannis Dragatsis,2 and Paula Dietrich2 Published in final edited form as: Int Rev Neurobiol. 2011; 98: 325–372. PMCID: PMC4458347 NIHMSID: NIHMS696061 PMID: 21907094
[75]. Diagnostic genetic testing for Huntington's disease; 1.David Craufurd 2, Rhona MacLeod 3, Marina Frontali 4, Oliver Quarrell5,Emilia K Bijlsma6,Mary Davi7,, Lena Elisabeth Hjermind8,Nayana Lahiri9, Paola Mandich10,Asunción Martinez11, Aad Tibben12, Raymund A Roos
[76]. Frank S. Treatment of Huntington's disease. Neurotherapeutics. 2014 Jan;11(1):153-60. doi: 10.1007/s13311-013-0244-z. PMID: 24366610; PMCID: PMC3899480.
[77]. Abdulrahman GO Jr. Therapeutic advances in the management of Huntington's disease. Yale J Biol Med. 2011 Sep;84(3):311-9. PMID: 21966050; PMCID: PMC3178862.
[78]. Recent advances of induced pluripotent stem cells application in neurodegenerative diseases NashwaAminab1XiaoningTana1QiannanRenaNingZhuacBensonO.A.BotchwayaZhiyingHudMarongFanga
[79]. New Hopes and Challenges for Treatment of Neurodegenerative Disorders: Great Opportunities for Young Neuroscientists Mahmoud Kiaei, PhD* Basic Clin Neurosci. 2013 Winter; 4(1): 3–4. PMCID: PMC4202552 PMID: 25337322
[80]. Alzheimer’s in a dish – induced pluripotent stem cell-based disease modelingSherida de Leeuw1,2 and Christian Tackenberg Transl Neurodegener. 2019; 8: 21. Published online 2019 Jul 12. doi: 10.1186/s40035-019-0161-0 PMCID: PMC6624934 PMID: 31338163
[81]. Important advances in Alzheimer’s disease from the use of induced pluripotent stem cells Fernanda Majolo, Daniel Rodrigo Marinowic, Denise Cantarelli Machado, and Jaderson Costa Da Costa J Biomed Sci. 2019; 26: 15. Published online 2019 Feb 6. doi: 10.1186/s12929-019-0501-5 PMCID: PMC6366077 PMID: 30728025
[82]. Induced pluripotent stem cells from Huntington’s disease patients: a promising approach to define and correct disease-related alterations Azra Fatima, Ricardo Gutiérrez-Garcia, and David Vilchez, PhD* Neural Regen Res. 2019 May; 14(5): 769–770. doi: 10.4103/1673-5374.249223 PMCID: PMC6375035PMID: 30688260
[83]. Chen RPY (2017) From Nose to Brain: The Promise of Peptide Therapy for Alzheimer’s Disease and Other Neurodegenerative Diseases. J Alzheimers Dis Parkinsonism 7:314. doi:10.4172/2161-0460.1000314
[84]. Peptide based therapeutics and their use for the treatment of neurodegenerative and other disease Mohammad HassanBaigaKhurshidAhmadaMohdSaeedbAhmed MAlharbibGeorge E.BarretocdGhulam MdAshrafeInhoChoia
[85]. Use of Peptides for the Management of Alzheimer’s Disease: Diagnosis and Inhibition Mohammad H. Baig, Khurshid Ahmad, Gulam Rabbani, and Inho Choi* Front Aging Neurosci. 2018; 10: 21.Published online 2018 Feb 7. doi: 10.3389/fnagi.2018.00021 PMCID: PMC5808296 PMID: 29467644
[86]. Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's. Nirale P1, Paul A1, Yadav KS2. Life Sci. 2020 Mar 15;245:117394. doi: 10.1016/j.lfs.2020.117394. Epub 2020 Feb 1
[87]. Nanoemulsions for "Nose-to-Brain" Drug Delivery. Bonferoni MC1,Rossi S1,Sandri G1,Ferrari F1,Gavini E2,Rassu G2,Giunchedi P2 Pharmaceutics, 17 Feb 2019, 11(2) DOI: 10.3390/pharmaceutics11020084 PMID: 30781585 PMCID: PMC6409749